Targeting CD157 in AML using a novel, Fc-engineered antibody construct

Antibody-based immunotherapy represents a promising strategy to eliminate chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated a novel Fc-engineered antibody against CD157 (MEN1112) for its suitability as immunotherapy in AML. CD157 was expressed in 97% of prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Krupka, Christina, Lichtenegger, Felix S., Köhnke, Thomas, Bögeholz, Jan, Bücklein, Veit, Roiss, Michael, Altmann, Torben, Do, To Uyen, Dusek, Rachel, Wilson, Keith, Bisht, Arnima, Terrett, Jon, Aud, Dee, Pombo-Villar, Esteban, Rohlff, Christian, Hiddemann, Wolfgang, Subklewe, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482610/
https://www.ncbi.nlm.nih.gov/pubmed/28415689
http://dx.doi.org/10.18632/oncotarget.16060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482610/
https://www.ncbi.nlm.nih.gov/pubmed/28415689
http://dx.doi.org/10.18632/oncotarget.16060

Ejemplares similares